The White House just handed FDA Commissioner Marty Makary a policy mandate: rewrite the rules to help US biotech outrun China.
The administration’s budget proposal includes FDA policy changes designed to accelerate clinical trials and cut regulatory costs for domestic companies. It’s framed explicitly as a competitiveness play — China’s biotech sector has been gaining ground fast, with state-backed capital flooding clinical pipelines over the past decade, and Washington noticed.
Makary has been vocal about streamlining FDA since taking the job. But a budget proposal is different from a press release. It means resources, it means political cover, and it means the changes are expected to actually happen. Faster trial pathways could shave months — potentially years — off development timelines for smaller US biotechs that can’t afford to wait.
The “who’s next” question matters here. If FDA adopts expedited review standards or reduced trial burden for certain categories, every company sitting on a Phase II asset starts recalculating.
Generic drugmakers feel it too. Less friction for domestic manufacturers plus tighter scrutiny on China-linked supply chains is a one-two punch.
The budget still needs to clear Congress, and the Senate HELP Committee, which oversees FDA’s authority and funding, will have a direct say.
— Sarah Chen